Market Overview - The Hang Seng Index (HSI) is expected to find short-term support around the 25,000 points level, following the Federal Reserve's decision to cut interest rates by 0.25 basis points in December, with market expectations for two additional rate cuts in 2026, which is higher than the Fed's own forecast [2] - Despite the ongoing interest rate cuts in the US and increased monetary policy easing in mainland China, the economic situation remains stable, and there is limited incentive for further policy adjustments in the short term [2] - The "14th Five-Year Plan" emphasizes expanding domestic demand and promoting technological self-reliance, with a focus on observing the outcomes of the Central Economic Work Conference [2] Economic Indicators - The total retail sales of consumer goods in China reached 45.6 trillion yuan in the first 11 months of 2025, reflecting a growth of 4.0%, which is 0.5 percentage points faster than the same period last year [7] - The retail sales of essential goods showed stable growth, with sales of grain, oil, and food increasing by 6.1%, and clothing and footwear sales rising by 3.5% [7] - The service retail sector grew by 5.4%, outpacing the growth of goods retail by 1.3 percentage points, with significant growth in leisure services and communication services [7] Corporate News - China Shenhua (1088) plans to acquire assets from its parent company for a total price of 133.6 billion yuan, intending to raise 20 billion yuan through A-share issuance to fund the cash portion of the transaction [9] - SenseTime (0020) announced the launch of its Kairos 3.0 model and the A1 module, aimed at enhancing embodied intelligence applications [9] - ByteDance, the parent company of TikTok, is expected to achieve a profit of approximately 50 billion USD in 2025, although there are reports suggesting discrepancies in the financial data [9] Sector Focus - The AI and technology sectors are seeing growth, with companies like Quark AI glasses and Doubao AI phones gaining traction, benefiting the supply chain [6] - The biopharmaceutical sector is also expected to thrive due to rising flu cases and favorable financing conditions for global biotech investments [6] - The insurance sector is benefiting from strong A-share performance, leading to improved investment returns [6]

中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 中核海得威「注射用硼[10B]法侖」臨床試驗申請獲批標誌着中核海得威BNCT藥械 協同研發領域取得突破性成果，正式邁入臨床轉化新階段，為「健康中國」戰略下 的精準腫瘤治療注入核科技新動能，為全球腫瘤治療貢獻「中國方案」。 本公司董事會欣然宣佈，近日，國家藥品監督管理局藥品審評中心(CDE)官網信 息顯示本公司附屬公司深圳市中核海得威生物科技有限公司「中核海得威」自主研 發的2.2類改良新藥「注射用硼[10B]法侖」（BNCT硼藥：硼中子俘獲療法，Boron neutron capture therapy）臨床試驗申請獲批（通知書編號：2025LP034 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻附屬公司中核海得威BNCT硼藥提交IND申請 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣佈，近日，國家藥品監督管理局藥品審評中心(CDE)官網信 息顯示本公司附屬公司深圳市中核海得威生物科技有限公司「中核海得威」申報的 「注射用硼[10B]法侖」已獲得國家藥品監督管理局藥品審評中心公開受理，受理號 為CXHL2501079。 中核海得威在研的「注射用硼[10B]法侖」針對對放化療不敏感、複發性、難治性、 浸潤性、中晚期、局部轉移的腫瘤具有顯著臨床優勢，且治療療程短（僅需1-2 次），毒副作用低、診療一體，代表了現代腫瘤精準醫學的發展 ...